Outcomes during follow-up period | Thiazolidinedione | |
---|---|---|
Pioglitazone | Rosiglitazone | |
N (%) | ||
Sudden cardiac arrest/ventricular arrhythmia | 295 | 233 |
 Sudden cardiac arrest | 217 (73.6) | 175 (75.1) |
 Ventricular arrhythmia | 60 (20.3) | 37 (15.9) |
 Both (contemporaneously) | 18 (6.1) | 21 (9.0) |
Sudden cardiac arrest/ventricular arrhythmia immediately precededa by hospitalization for an acute ischemic event | 0 (0.0) | c |
Sudden cardiac arrest/ventricular arrhythmia immediately precededa by emergency department presentation or hospitalization for hypoglycemia | c | c |
Measure of sudden cardiac arrest/ventricular arrhythmia occurrence | Incidence rate (95% confidence interval) | |
---|---|---|
Unadjusted, per 1000 person-years | 2.67 (2.37–2.99) | 3.14 (2.75–3.57) |
Age- and sex-standardizedb, per 1000 person-years | 2.89 (2.55–3.24) | 3.38 (2.92–3.85) |
Relative effect estimates for sudden cardiac arrest/ventricular arrhythmia | Hazard ratio (95% confidence interval) | |
---|---|---|
Unadjusted†| 1.00 (referent) | 1.16 (0.98–1.38) |
Confounder-adjusted‡, also see ■in Fig. 2 | 1.00 (referent) | 0.91 (0.75–1.10) |